Grace Therapeutics (GRCE) Insider Trades, Congress & Funds

Smart money at a glance

Filings to Nov 14, 2026

Net buying: insiders sold $0 and bought $783K on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: +$783K net
CongressSTOCK Act, 180 days: None
Big funds13F, latest quarter: No large changes
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about GRCE filings

Are insiders buying or selling Grace Therapeutics, Inc. (GRCE) stock?

Net buying: insiders sold $0 and bought $783K of GRCE stock on the open market in the 90 days to Nov 14, 2026, according to SEC Form 4 filings. The largest was Opaleye Management Inc. (10% owner), who bought $569K. The latest filing was on Nov 6, 2026.

Which members of Congress have traded GRCE recently?

None. No member of Congress disclosed a GRCE trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this GRCE smart-money data?

This summary uses filings available on Nov 14, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

Filings could not be loaded.

8 funds hold a position and insiders have been net buying.

Questions about GRCE filings

Are insiders buying or selling Grace Therapeutics, Inc. (GRCE) stock?

Which members of Congress have traded GRCE recently?

None. No member of Congress disclosed a GRCE trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this GRCE smart-money data?

Insiders

What insiders are doing

11 trades · 6 mo

Bought$807K

Buys (3)

OM
Opaleye Management Inc.
10% · Held by Opaleye, L.P. · Nov 6
$33K
bought
OM
Opaleye Management Inc.
10% · Held by Opaleye, L.P. · Oct 26
$159K
bought
Signals like this: n=2459, 52% finished lower at D15, median -0.4% vs SPY +0.2%
OM
Opaleye Management Inc.
10% · Held by Opaleye, L.P. · Oct 21
$8K
bought

2 more trades

Pro opens all of them for $16.50/month, paid yearly.

Unlock all 2 trades

Unlock everything for $29/month

Unlock for $29/month

Reported Nov 12, 2026

Earnings came in 24.6% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Nov 12, 2026

Period ending

Sep 30, 2026

Earnings per share

-$0.16+24.60% beat

-$0.21 expected

Revenue

$0.00

SEC filing · No operating revenue

EPS: Yahoo Finance

Next report

What the street expects next

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Nov 12, 2026	-$0.16est. -$0.21	+24.60%beat	$0.00SEC filing	No year-ago quarter
Jun 30, 2026Reported Aug 13, 2026	-$0.18est. -$0.18	+0.98%in line	$0.00SEC filing	No year-ago quarter
Mar 31, 2026Reported Jun 18, 2026	-$0.08est. -$0.20	+58.94%beat	$0.00Alpha Vantage	-100.0%from $8.0K
Dec 31, 2025Reported Feb 12, 2026	-$0.19est. -$0.39	+51.59%beat	$0.00Alpha Vantage	No year-ago quarter
Sep 30, 2025Reported Nov 13, 2025	-$0.08est. -$0.34	+76.47%beat	$0.00Alpha Vantage	No year-ago quarter
Jun 30, 2025Reported Aug 12, 2025	-$0.29est. -$0.31	+6.45%beat	$0.00Alpha Vantage	No year-ago quarter
Mar 31, 2025Reported Jun 23, 2025	$0.05est. -$0.40	+112.55%beat	$8.0KAlpha Vantage	No year-ago quarter
Dec 31, 2024Reported Feb 13, 2025	-$0.51est. -$0.46	-11.67%miss	$0.00Alpha Vantage	No year-ago quarter

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $1.84
High: $1.88
Low: $1.80
Prev close: $1.86
52-wk high: $5.18
52-wk low: $1.67
Mkt cap: $39.0M
ROE: -36.2%
Fwd P/E: 2.2x
Beta: 0.41
P/S: 197.8x
P/B: 0.8x
Profit margin: +0.0%
Op margin: +0.0%

Sep 2025 to Jun 2026

What it sold, what it cost, what was left.

RevenueProfit

Sep 2025Dec 2025Mar 2026Jun 2026

Income statement, 4 periods, all values in US dollars
USD	Sep 2025	Dec 2025	Mar 2026	Jun 2026
What came in
RevenueTotal revenue	$0	$0	$0	$0
Cost of what it soldCost of revenue	$2.0K	$4.1K	$2.0K	—
Gross profit	-$2.0K	-$4.1K	-$2.0K	—
What it spent
Research and development	$792.2K	$633.9K	$420.0K	$697.0K
Sales and adminSelling, general and administrative	$2.7M	$2.7M	$308.6K	$1.7M
Other operating costsOperating costs not itemised in the filing's summary	—	—	$2.3M	$13.4M
Total operating expenses	$3.5M	$3.4M	$3.0M	$15.8M
What was left
Operating profitOperating income	-$3.5M	-$3.4M	-$3.0M	-$15.8M
Profit before tax	-$1.3M	-$3.2M	-$2.9M	-$15.8M
TaxIncome tax expense	—	—	-$1.7M	—
Net profitNet income	-$1.3M	-$3.2M	-$1.2M	-$15.8M
EBITDAEarnings before interest, tax, depreciation, amortisation	-$3.5M	-$3.4M	-$3.0M	-$15.8M

Technicals

Price structure

This stock is under pressure.

Trend

Under pressure

0 / 100

RSI 14

42balanced

20D volatility

56%annualized

52-week range

$1.81

$1.67$5.18

20D support

$1.67recent floor

20D resistance

$2.07recent ceiling

Returns

5D +1.7%20D -7.2%60D -17.7%

Price vs moving averages

SMA20 -3.8%SMA50 -10.2%SMA200 -33.8%

Volume pace

1.14xvs prior 20D

Quarter / reported

Earnings per share

Beat or miss

Revenue / income

Revenue vs last year

Sep 30, 2026Nov 12, 2026

-$0.16est. -$0.21

+24.60%

$0.00SEC filing

No year-ago quarter

Jun 30, 2026Aug 13, 2026

-$0.18est. -$0.18

+0.98%

$0.00SEC filing

No year-ago quarter

Mar 31, 2026Jun 18, 2026

-$0.08est. -$0.20

+58.94%

$0.00Alpha Vantage

-100.0%from $8.0K

Dec 31, 2025Feb 12, 2026

-$0.19est. -$0.39

+51.59%

$0.00Alpha Vantage

No year-ago quarter

Sep 30, 2025Nov 13, 2025

-$0.08est. -$0.34

+76.47%

$0.00Alpha Vantage

No year-ago quarter

Jun 30, 2025Aug 12, 2025

-$0.29est. -$0.31

+6.45%

$0.00Alpha Vantage

No year-ago quarter

Mar 31, 2025Jun 23, 2025

$0.05est. -$0.40

+112.55%

$8.0KAlpha Vantage

No year-ago quarter

Dec 31, 2024Feb 13, 2025

-$0.51est. -$0.46

-11.67%

$0.00Alpha Vantage

No year-ago quarter

Income statement, 4 periods, all values in US dollars
USD	Sep 2025	Dec 2025	Mar 2026	Jun 2026
What came in
RevenueTotal revenue	$0	$0	$0	$0
Cost of what it soldCost of revenue	$2.0K	$4.1K	$2.0K	—
Gross profit	-$2.0K	-$4.1K	-$2.0K	—
What it spent
Research and development	$792.2K	$633.9K	$420.0K	$697.0K
Sales and adminSelling, general and administrative	$2.7M	$2.7M	$308.6K	$1.7M
Other operating costsOperating costs not itemised in the filing's summary	—	—	$2.3M	$13.4M
Total operating expenses	$3.5M	$3.4M	$3.0M	$15.8M
What was left
Operating profitOperating income	-$3.5M	-$3.4M	-$3.0M	-$15.8M
Profit before tax	-$1.3M	-$3.2M	-$2.9M	-$15.8M
TaxIncome tax expense	—	—	-$1.7M	—
Net profitNet income	-$1.3M	-$3.2M	-$1.2M	-$15.8M
EBITDAEarnings before interest, tax, depreciation, amortisation	-$3.5M	-$3.4M	-$3.0M	-$15.8M

USD

Sep 2025

Dec 2025

Mar 2026

Jun 2026

What came in

RevenueTotal revenue

Cost of what it soldCost of revenue

$2.0K

$4.1K

$2.0K

—

Gross profit

-$2.0K

-$4.1K

-$2.0K

—

What it spent

Research and development

$792.2K

$633.9K

$420.0K

$697.0K

Sales and adminSelling, general and administrative

$2.7M

$308.6K

$1.7M

Other operating costsOperating costs not itemised in the filing's summary

—

$2.3M

$13.4M

Total operating expenses

$3.5M

$3.4M

$3.0M

$15.8M

What was left

Operating profitOperating income

-$3.5M

-$3.4M

-$3.0M

-$15.8M

Profit before tax

-$1.3M

-$3.2M

-$2.9M

-$15.8M

TaxIncome tax expense

—

-$1.7M

—

Net profitNet income

-$1.3M

-$3.2M

-$1.2M

-$15.8M

EBITDAEarnings before interest, tax, depreciation, amortisation

-$3.5M

-$3.4M

-$3.0M

-$15.8M

Grace Therapeutics, Inc.

Smart money at a glance

What do analysts expect?

Questions about GRCE filings

Questions about GRCE filings

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 24.6% above what analysts expected.

What the street expects next

Previous reports

What it sold, what it cost, what was left.

Price structure

Ask it in Claude or ChatGPT.

Grace Therapeutics, Inc.

Smart money at a glance

What do analysts expect?

Questions about GRCE filings

Questions about GRCE filings

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 24.6% above what analysts expected.

What the street expects next

Previous reports

What it sold, what it cost, what was left.

Price structure

Ask it in Claude or ChatGPT.

Grace Therapeutics, Inc.

Overview

Questions about GRCE filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

Grace Therapeutics, Inc.

Overview

Questions about GRCE filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.